Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)

References

• AbramsTJLeeJBMurrayLJSU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancerMol Cancer Ther20032471812748309
   PubMed Web of Science ®Google Scholar
• AbramsTJMurrayLJPesentiEPreclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancerMol Cancer Ther2003210112114578466
   PubMed Web of Science ®Google Scholar
• AhmadTEisenTKinase inhibition with BAY 43–9006 in renal cell carcinomaClin Cancer Res20041018 Pt 26388S92S15448036
   PubMedGoogle Scholar
• BaratteSSaratiSFrigerioEQuantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extractionJ Chromatogr A200410241–2879414753710
   PubMed Web of Science ®Google Scholar
• BardosJLAschcroftMHypoxia-inducible factor-1 and oncogenic signallingBioessays200426262914988927
   PubMedGoogle Scholar
• BergersGSongSMeyer-MorseNBenefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitorsJ Clin Invest200311112879512727920
   PubMed Web of Science ®Google Scholar
• BlankeCDCorlessCLState-of-the art therapy for gastrointestinal stromal tumorsCancer Invest2005232748015945512
   PubMed Web of Science ®Google Scholar
• CorlessCLFletcherJAHeinrichMCBiology of gastrointestinal stromal tumorsJ Clin Oncol20042238132515365079
   PubMed Web of Science ®Google Scholar
• De MulderPHRoigasJGillessenSA phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine refractory metastatic renal cell carcinoma (mRCC)2006American Society of Clinical Oncology 42th Annual Meeting2–6 JuneAtlanta, USA
   Google Scholar
• DemetriGDvon MehrenMBlankeCDEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsN Engl J Med20023474728012181401
   PubMed Web of Science ®Google Scholar
• DemetriDGvan OosteromABlacksteinMPhase 3 multicenter, randomized, double-bind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST2005American Society of Clinical Oncology 41st Annual Meeting13–17 MayOrlando, Florida, USA
   Google Scholar
• DeprimoSEBelloCLSmeragliaJSoluble protein biomarkers of pharmacodynamic activity of the multitargeted tyrosine kinase inhibitor SU11248 in patients with metastatic renal cell carcinoma200596th Annual Meeting of the American Association for Cancer Research16–21 AprilAnaheim, California, USA
   Google Scholar
• EscudierBSzczylikCEisenTRandomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)2005American Society of Clinical Oncology 41st Annual Meeting13–17 MayOrlando, Florida, USA
   Google Scholar
• FabianMABiggsWHTreiberDKA small molecule-kinase interaction map for clinical kinase inhibitorsNat Biotechnol2005233293615711537
   PubMed Web of Science ®Google Scholar
• FaivreSDelbaldoCVeraKSafety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancerJ Clin Oncol200624253516314617
   PubMed Web of Science ®Google Scholar
• FerraraNHillanKJGerberHPDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNat Rev Drug Discov2004339140015136787
   PubMed Web of Science ®Google Scholar
• GeorgeSCasaliPGBlayJPhase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST2006American Society of Clinical Oncology 42th Annual Meeting2–6 JuneAtlanta, USA
   Google Scholar
• HainsworthJDSosmanJASpigelDRTreatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinibJ Clin Oncol20052378899616204015
   PubMed Web of Science ®Google Scholar
• HeinrichMCCorlessMCDemetriGDKinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorJ Clin Oncol2003214342914645423
   PubMed Web of Science ®Google Scholar
• HudesGCarducciMTomczakPA phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR+IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC)2006American Society of Clinical Oncology 42th Annual Meeting2–6 JuneAtlanta, USA
   Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med200435023354215175435
   PubMed Web of Science ®Google Scholar
• KamuraTSatoSIwaiKActivation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complexProc Natl Acad Sci U S A20009710430510973499
   PubMed Web of Science ®Google Scholar
• KerbelRFolkmanJClinical translation of angiogenesis inhibitorsNat Rev Cancer200227273912360276
   PubMed Web of Science ®Google Scholar
• KulkeMLenzHJMeropolNJA phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs)2005American Society of Clinical Oncology 41st Annual Meeting13–17 MayOrlando, Florida, USA
   Google Scholar
• LamJSLeppertJTBelldegrunASNovel approaches in the therapy of metastatic renal cell carcinomaWorld J Urol2005232021215812574
   PubMed Web of Science ®Google Scholar
• LatifFToryKGnarraJIdentification of the von Hippel-Lindau disease tumor suppressor geneScience19932601317208493574
   PubMed Web of Science ®Google Scholar
• LenzHMarshallJRosenLPhase II trial of SU11248 in patients with metastatic colorectal cancer (MCRC) after failure of standard chemotherapy2006American Society of Clinical Oncology Gastrointestinal 4th Annual Meeting27–29 JanuarySan Fransisco, USA
   Google Scholar
• MakiRGFletcherJAHeinrichMCSU11248 in patients with imatinib-resistant GIST : results from a continuation trial2005American Society of Clinical Oncology 41st Annual Meeting13–17 MayOrlando, Florida, USA
   Google Scholar
• MendelDBLairdADXinXIn vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipClin Cancer Res200393273712538485
   PubMed Web of Science ®Google Scholar
• MillerKDBursteinHJEliasADPhase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC)2005San Antonio Breast Cancer Symposium 28th Annual Meeting8–11 DecemberSan Antonio, Texas, USA
   Google Scholar
• MorimotoAMTanNWestKGene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitorOncogene20042316182614985702
   PubMed Web of Science ®Google Scholar
• MotzerRJBanderNHNanusDMRenal-cell carcinomaN Engl J Med1996335865758778606
   PubMed Web of Science ®Google Scholar
• MotzerRJBacikJSchwartzLHPrognostic factors for survival in previously treated patients with metastatic renal cell carcinomaJ Clin Oncol2004224546314752067
   PubMed Web of Science ®Google Scholar
• MotzerRJRiniBIBukowskiRMSunitinib in patients with metastatic renal cell carcinomaJAMA200629525162416757724
   PubMed Web of Science ®Google Scholar
• MotzerRJMichaelsonMDRedmanBGActivity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinomaJ Clin Oncol200624162416330672
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakMDPhase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)2006American Society of Clinical Oncology 42st Annual Meeting2–6 JuneAtlanta, USA
   Google Scholar
• MurrayLJAbramsTJLongKRSU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis modelClin Exp Metastasis2003207576614713109
   PubMed Web of Science ®Google Scholar
• O’FarrellAMForanJMFiedlerWAn innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patientsClin Cancer Res2003954657614654525
   PubMed Web of Science ®Google Scholar
• PatelPHChagantiRSKMotzerRJTargeted therapy for metastatic renal cell carcinomaBr J Cancer2006946141916465192
   PubMed Web of Science ®Google Scholar
• RatainMJEisenTStadlerWMFinal findings from a Phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)2005American Society of Clinical Oncology 41st Annual Meeting13–17 MayOrlando, Florida, USA
   Google Scholar
• RohrmannKStaehlerMHasekeNImmunotherapy in metastatic renal cell carcinomaWorld J Urol20052319620115806434
   PubMed Web of Science ®Google Scholar
• RonnenEAKondaguntaGVLauCA phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC)2006American Society of Clinical Oncology 42th Annual Meeting2–6 JuneAtlanta, USA
   Google Scholar
• ShaheenRMTsengWWDavisDWTyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanismsCancer Res2001611464811245452
   PubMed Web of Science ®Google Scholar
• SocinskiMANovelloSSanchezJMEfficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial2006American Society of Clinical Oncology 42th Annual Meeting2–6 JuneAtlanta, USA
   Google Scholar
• TonerGCMitchellPLDe BoerRPET imaging study of SU11248 in patients with advanced malignancies2003American Society of Clinical Oncology 39th Annual Meeting31 May–3 JuneUSA
   Google Scholar
• Van GlabbekeMVerweijJCasaliPGInitial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group studyJ Clin Oncol200523579580416110036
   PubMed Web of Science ®Google Scholar
• VerweijJCasaliPGZalcbergJProgression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomised trialLancet200436411273415451219
   PubMed Web of Science ®Google Scholar
• WangGLSemenzaGLGeneral involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxiaProc Natl Acad Sci U S A199390430488387214
   PubMed Web of Science ®Google Scholar
• WillettCGBoucherYdi TomasoEDirect evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerNat Med200410145714745444
   PubMed Web of Science ®Google Scholar
• YangJCHaworthLSherryRMA randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancerN Engl J Med20033494273412890841
   PubMed Web of Science ®Google Scholar
• YeeKWSchittenhelmMO’FarrellAMSynergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cellsBlood20041044202915304385
   PubMed Web of Science ®Google Scholar